Advances and Challenges in the Use of Nanoparticles to Optimize PK/PD Interactions of Combined Anti-Cancer Therapies

Publisher： Bentham Science Publishers

E-ISSN： 1875-5453|15|8|818-828

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.15, Iss.8, 2014-10, pp. : 818-828

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Translational PK-PD modeling in pain

By Yassen Ashraf  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 40, Iss. 3, 2013-06 ,pp. : 401-418

Springer Publishing Company

Access to resources Recommend Favorite

Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage

By Zisowsky Jochen   Fuseau Eliane   Bruderer Shirin   Krause Andreas   Dingemanse Jasper  

European Journal of Clinical Pharmacology, Vol. 70, Iss. 4, 2014-04 ,pp. : 409-419

Springer Publishing Company

Access to resources Recommend Favorite

Targeted Anti-Cancer Therapies for Renal Cancer

By Amato Robert J.   Jac Jaroslaw  

Drugs, Vol. 66, Iss. 17, 2006-01 ,pp. : 2161-2171

Adis International

Access to resources Recommend Favorite

Streamlining the PK/PD data transfer process

By Collins Arthur  

Pharmaceutical Programming, Vol. 3, Iss. 1, 2010-06 ,pp. : 24-28

Maney Publishing

Access to resources Recommend Favorite

Sample Size Computations for PK/PD Population Models

By Kang Dongwoo   Schwartz Janice   Verotta Davide  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 32, Iss. 5-6, 2005-12 ,pp. : 685-701

Springer Publishing Company

Access to resources Recommend Favorite